Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
Recruiting now · Phase 1
Conditions studied: Reproductive Disorder, Neurodegeneration, SARS-CoV 2, Long COVID
In brief
The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.
Key facts
- Study ID
- NCT07224490
- Run by
- Stephanie B. Seminara, MD
- People needed
- 40
- Starts
- 2026-03-10
- Expected to finish
- 2030-05-01
- Last updated by the study team
- 2026-07-13
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Female (ages 18-45 years) or Male (ages 18-60 years)
- No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and its method of administration
- For women, negative serum hCG pregnancy test
- For cases, diagnosis of post-covid-19 syndrome
- For controls, history of prior covid infection but no diagnosis of post-covid-19 syndrome
You may not qualify if…
- Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in/completion of the protocol or the interpretation of results
- Active use of illicit drugs (not including marijuana)
- For women,
- Pregnant
- Trying to become pregnant during protocol participation
- Breast feeding
- Surgical or natural menopause
Where it is running
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.